According to Stock Rover* in the trailing 1-year, the Dividend Kings have returned +22.1% (blue line) compared to +37.1% for the S&P 500 Index benchmark (red line), as seen in the chart below ...

Shares of AbbVie (ABBV) are sliding on Monday after the company’s drug candidate for schizophrenia failed to meet the key goal in two ...

AbbVie (ABBV) shares dropped 11% premarket as late-stage trials for schizophrenia drug emraclidine did not meet primary ...

Barclays analyst Carter Gould keeps an Overweight rating on AbbVie (ABBV) after the company disclosed that both of its registrational studies of emraclidine for schizophrenia failed to meet their ...

--On pace for largest percent decrease since June 25, 2019, when it fell 16.25% --Currently down four consecutive days; down 14.17% over this period ...

AbbVie said on Monday that an experimental schizophrenia drug it gained through an $8.7 billion deal for Cerevel Therapeutics failed two mid-stage studies, sending the drugmaker's shares plunging 12.5 ...

EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their primary endpoint Emraclidine was well-tolerated with an adverse event profile consistent with ...

AbbVie shares, which hit a 52-week high in late October after the drugmaker posted quarterly earnings that topped Wall Street's expectations and raised its dividend by nearly 6%, were recently down ...

Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry’s largest trade group, the Biotechnology ...

AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its anti-amyloid antibody ALIA-1758, which is in phase 1 testing. If consummated ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Americold Realty Trust, the largest tradeable cold-storage REIT, has underperformed due to management miscalculations and ...